Showing results (11-20 of 62) with videos related to
Sort By:
Pageof 7
Environmental Health : a Global Access Science Source|September 5, 2015
Temporal clustering of neuroblastic tumours in children and young adults from Northern EnglandColin R Muirhead, Deborah A Tweddle, Nermine O Basta, et al.Cancer Letters|February 16, 2010
MYCN oncoprotein targets and their therapeutic potentialEmma Bell, Lindi Chen, Tao Liu, et al.Clinical & Experimental Metastasis|May 27, 2014
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxibEmma Bell, Frida Ponthan, Claire Whitworth, et al.Pediatric Hematology and Oncology|January 11, 2011
Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survivalSimon Bomken, Beverley Davies, Leeai Chong, et al.International Journal of Oncology|February 3, 2018
Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumoursLindi Chen, Arman Esfandiari, William Reaves, et al.Cancer Genetics and Cytogenetics|January 11, 2007
High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arraysJane Carr, Nick P Bown, Marian C Case, et al.Environmental Health : a Global Access Science Source|January 24, 2026
Temporal clustering of neuroblastic tumours in children and young adults from ScotlandNermine Basta, Min Li, Louise Hayes, et al.Cancer Research|February 21, 2006
Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapseJane Carr, Emma Bell, Andrew D J Pearson, et al.Oncotarget|April 7, 2015
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastomaLindi Chen, Raphaël F Rousseau, Steven A Middleton, et al.Cancer Letters|July 26, 2003
The p53 pathway and its inactivation in neuroblastomaDeborah A Tweddle, Andrew D J Pearson, Michelle Haber, et al.Pageof 7